Q4 EPS Estimate for Bausch Health Cos Lifted by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Equities research analysts at Zacks Research upped their Q4 2026 EPS estimates for Bausch Health Cos in a research report issued on Friday, September 26th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.14 for the quarter, up from their previous forecast of $1.13. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q1 2027 earnings at $0.88 EPS and FY2027 earnings at $4.38 EPS.

Separately, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 20th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.00.

Bausch Health Cos Stock Down 0.3%

Shares of NYSE BHC opened at $6.45 on Monday. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. Bausch Health Cos has a 52 week low of $4.25 and a 52 week high of $9.85. The firm has a 50-day moving average price of $6.92 and a 200 day moving average price of $6.06. The stock has a market capitalization of $2.39 billion, a price-to-earnings ratio of 24.81 and a beta of 0.48.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The company had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS.

Insider Transactions at Bausch Health Cos

In other news, Director John Paulson purchased 34,721,118 shares of the stock in a transaction dated Thursday, August 14th. The stock was acquired at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the acquisition, the director directly owned 70,755,869 shares in the company, valued at $636,802,821. This represents a 96.35% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought a total of 37,964,167 shares of company stock worth $333,757,793 in the last ninety days. Insiders own 19.97% of the company’s stock.

Institutional Investors Weigh In On Bausch Health Cos

Hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC grew its holdings in shares of Bausch Health Cos by 4,134.7% during the first quarter. Acadian Asset Management LLC now owns 673,316 shares of the company’s stock worth $4,347,000 after buying an additional 657,416 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Bausch Health Cos by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after buying an additional 467,270 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Bausch Health Cos by 688.2% during the fourth quarter. Two Sigma Investments LP now owns 265,461 shares of the company’s stock worth $2,140,000 after buying an additional 231,781 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Bausch Health Cos during the fourth quarter worth about $468,000. Finally, Nomura Holdings Inc. grew its holdings in shares of Bausch Health Cos by 106.2% during the first quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock worth $151,366,000 after buying an additional 12,050,000 shares in the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.